Cognition Therapeutics (NASDAQ:CGTX – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03, FiscalAI reports.
Here are the key takeaways from Cognition Therapeutics’ conference call:
- Cognition says it has aligned with the FDA on a planned Phase III trial of zervimesine for mild-to-moderate DLB, with one pivotal study potentially sufficient, subject to FDA review of the completed data. The company aims to start the trial in mid-2027.
- The planned trial will use hallucinations and delusions, measured by the NPI-2, as its primary endpoint, with daily living activities as a key secondary endpoint. Management cited favorable Phase II SHIMMER results across DLB symptoms, but the Phase III study will need to confirm whether the treatment slows disease progression.
- The company is evaluating funding options for the DLB trial. Management said the revised design requires less than half the roughly 750 participants initially contemplated, but did not provide a new trial cost; current cash is expected to fund operations only into the fourth quarter of 2027.
- The 545-participant START Phase II study in mild cognitive impairment and early Alzheimer’s disease is fully enrolled and funded by the NIA, with top-line results expected in the second half of 2027. Management said baseline data have not yet been analyzed for comparison with the prior SHINE study.
Cognition Therapeutics Stock Performance
Cognition Therapeutics stock traded up $0.05 during mid-day trading on Friday, reaching $0.69. The company’s stock had a trading volume of 282,194 shares, compared to its average volume of 605,701. The company has a market capitalization of $65.33 million, a price-to-earnings ratio of -4.58 and a beta of 1.84. Cognition Therapeutics has a 12 month low of $0.55 and a 12 month high of $1.82. The business’s 50 day simple moving average is $0.88 and its 200 day simple moving average is $1.05.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on CGTX. HC Wainwright reiterated a “buy” rating on shares of Cognition Therapeutics in a report on Monday, October 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday, September 21st. Finally, Wall Street Zen downgraded Cognition Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cognition Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.33.
Get Our Latest Analysis on Cognition Therapeutics
About Cognition Therapeutics
Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.
Cognition Therapeutics’ lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.
Read More
- Five stocks we like better than Cognition Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Cognition Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognition Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
